Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks to you both!
Minimally, the FDA could approve EEMT and that would lead to an increase in prescriptions from doctors who are currently reluctant to prescribe because it is not approved.
The FDA might actually ACT on their documented claims that compounding pharmacies are creating product with questionably quantifiable hormone amounts. If so, we are very well equipped to create a commercially produced T gel specifically designed for women. It could be available at pharmacies (like eemt is now) even though it might not be an FD A approved product.
If a T product is approved for women, I believe we have patent rights (my memory is not 100% On this/Antares has rights too.)
None of the above scenarios will affect CVRs unless Libigel is approved, but they would affect our revenue.
JTFM, Thanks for the info and yes, it would be great if that criteria was established!
Still a relevant topic for discussion in ob/gyn journals:
https://www.mdedge.com/obgyn/article/178614/female-sexual-dysfunction/low-sexual-desire-appropriate-use-testosterone/page/0/4
This could be a real sleeper! Thanks Silvr.
JTFM, Thank you.
Wonder why and why now? After hours on a Friday. Kind of under the radar.
Thank you!
Hi RG. Don't know. Please share it you learn anything. Thanks.
Guess who worked on the project?
https://www.linkedin.com/in/joannezborowski
Hi JTFM, This information about TherapeuticsMd is relevant because they are about to launch a product that in the past, was only available as a compounded product. Strong parallel to Libigel IMO.
https://www.fiercepharma.com/pharma/therapeuticsmd-wins-fda-nod-for-first-bioidentical-menopause-hormone-combo-drug
The sheer number of compounded prescriptions is still our most important driver.
Great news. Thanks 174!!
Maybe nothing but why is this new Baudette position temporary?
Contracts Support Associate - Temporary Position
The temporary Contracts Support Associate position is responsible for daily data entry as it relates to contract support related activities. This includes order processing, shipping paperwork, invoicing, advanced ship notices and other duties as assigned. This temporary position is expected to be for 3 to 6 months in duration.
Position Responsibilities:
1. Order Entry - Receipt-entry (EDI, Fax, e-mail).
2. Shipping-Invoicing - Prepare all docs pre and post shipment, maintain files, send invoices and advanced ship
3. CSII Orders - Process, verify, track orders, and maintain electronic 222 log.
4. Performs other duties as assigned or requested.
Position Requirements:
This position requires an Associates degree and 1-2 years related experience or training, or equivalent combination of education and experience. This position also requires:
- Ability to manage multiple projects and competing priorities.
- Ability to work well under pressure and to work within short deadlines.
- Excellent computer skills in Microsoft Windows Environment. Must include Excel with demonstrated aptitude for Access and/or database management.
- Excellent organizational and multitasking skills, strong work ethic, and emphasis on attention to details.
- Work independently while effectively communicating and coordinating work efforts with others.
Apply Now! | Top
I've made reference to products that I thought were part of the Wellspring acquisition but I now believe that they were not. Our acquisition was announced was part of a conference call. Weird. I immediately went to the Wellspring website and saw two groups of well known OTC products, one US, one Canadian: Bactine, Bonine, FDS, etc. Those products were displayed on the link to Wellspring from the ANI website until very recently. They have since been removed.
In September 2017, the Audax Group bought the consumer products division of Wellspring. I believe they still own all of those products.
https://www.businesswire.com/news/home/20170927005914/en/Audax-Private-Equity-Announces-Acquisition-Wellspring-Consumer
I think it's sleazy that the company website was not corrected for a year and that ANI did not check for accuracy before announcing the acquisition. Does anyone else feel that this was misleading? Disappointed.
What am I missing?
I was wondering if we were about to receive significant news.
Thanks Catty. Merry Christmas to you too!
Let me preface this post by stating that I am not well versed in corporate finance. From what I have researched on-line however, I believe that our exaggerated pps drop is related to our recent news:
ANI Pharmaceuticals Enters into Separate Privately Negotiated Agreements with Certain Holders of its Convertible Notes
There was a post on Stocktwits that hedge funds are buying ANIP. What we see happening could easily be the shorting of stock by the folks whose convertible notes were purchased by the company. The company PR was issued without detail intentionally. If you Google "convertible hedge agreement" you will see that these arrangements exist and they are probably incredibly successful in times of market panic. Make money going down and then up.
Hold onto your shares ANIP devotees. We know that the company is resilient and adaptable. Art has hedged the political generic drug BS drama with a strong over the counter products acquisition. I may be wrong on this, as I originally stated, I am self taught. Meanwhile, Bactine is a great addition to every first aid kit. Buy some.
The Career link also shows that they are still running a second shift.
Obviously disappointed with the current pps but not worried longer term. Very interested in Wellspring revenue.
A little insider buying would make the holiday merry.
Great post. Thanks JTFM.
Hi Jeff, Thanks. We still need more info though. Nice to see a little green on a red day. J
Thanks Silvr. Hoping for success.
OT: Check out this UK company in phase 2 for treatment for advanced breast cancer and other diseases using a derivative of broccoli. I just think this is fascinating.
http://evgen.com/pipeline/
Amen to that! Thanks Silvr!
Hi Catty, Look at the 3 year chart. Moving forward, higher highs and higher lows. Patience. Be well. J
Thank you. Art will need to be more forthcoming with information about this financing in the not too distant future.
If notes are converted, is an SEC form generated? How do we know if the action has or has not happened? That's a lot of shares!
dasgrunt, I have read this many times and I do not understand it. If I get around to calling the company I will post what I learn.
Thank you.
dasgrunt, Two great points. Thank you. We need more info about the senior convertible notes. Very complicated and isn't the date soon?
Couldn't that issue be the "lid" on our pps?
Did not know about the interest in injectables. Makes me think of an Antares Pharma merger?
The Wellspring acquisition seems to be a big positive. Thanks for the input!
Agree! Still a very good quarter.
Thanks dasgrunt!
Thanks for that info JTFM! Could very well be that a move like that from a very big pharm could trigger trouble in the sector.
I think we will see a big surprise from at least Pindolol. Wellspring was ID T Australia's "other partner." Bigger profit.
Hi Catty, Not buying it (the theory). If you Google ANI pharma Oakville linkedin, you will see that all the smart kids have been working in Canada for a while (chemist, engineers, etc). I think they were working there during the last quarter. Last quarter was the anomaly, IMO.
Cantor Fitzgerald says we are a buy.I think they are correct.
I learned from members of this board that a small float can lead to excessive punishment. It can also lead to a fast and disproportionate reward.
Earnings on 11/6. Before the bell.Best of luck to all here.
Not sure what to think. Hard to see what they're up to. Art is a problem solver.
Hi BB, Thanks for the positive message. All the best to you, your family, and our own board regulars. Enjoy this beautiful New York fall weather.
As a company, we are in cocoon mode now but soon to emerge.
I am very interested in the Wellspring acquisition and thinking that Art Przybyl is a CEO who is looking for shareholder value.
Thank you BB.
Bagel,
I thought the dates were interesting and in a geographic area to piggyback with the NYC Cantor Fitzgerald conference.
The thrust of the conference was "manufacturing, packaging, laboratory services" very much aligning with ANI new acquisition and game plan.
Conference ad indicates:
"2018 Exhibitor Registration is SOLD OUT: to be added to the wait list, send contact info. to: kbrooks@rodmanmedia.com"
If accurate, high level of interest. All good.
This conference, sponsored by ANI, Wellspring and others, was on the Wellspring website but did not get a PR. Note the list of speakers from big pharma and the FDA:
http://conference.contractpharma.com